Novel Androgen Receptor Target Promotes Prostate Cancer Tumorigenesis by Regulating Glycolysis

Strategic Insights -

Researchers at the University of Nebraska Medical Center have made a significant discovery in the field of oncology, unveiling a novel androgen receptor target gene called ECD that plays a pivotal role in promoting prostate cancer tumorigenesis by regulating glycolysis. The study, published in the journal Oncogene, highlights the critical importance of ECD in maintaining PC oncogenesis, providing valuable insights into the molecular mechanisms underlying prostate cancer development and progression.

Key Takeaways:

  • The androgen receptor (AR)-mediated signaling pathway is essential for prostate cancer (PC) tumorigenesis, and ECD is a novel AR target gene that plays a crucial role in promoting PC tumorigenesis.
  • ECD overexpression is associated with shorter survival in PC patients, and its overexpression predicts a poorer prognosis.
  • ECD is required for the stability and expression of key glycolytic genes, contributing to the increased glucose uptake and glycolysis observed in PC cells.
  • The RNA-seq analysis of mouse tumors revealed an increase in mRNA levels of several glycolytic genes, highlighting the functional importance of ECD in regulating glycolysis.
  • ECD associates with mRNA of key glycolytic genes and is required for their stability, demonstrating its role as an RNA-binding protein.
  • The study demonstrated that Enzalutamide treatment decreased ECD levels, and ECD knockout (KO) in PC cells reduced oncogenic traits, suggesting a functional role of ECD in maintaining PC oncogenesis.
  • The University of Nebraska Medical Center researchers, led by Asher Rajkumar Rajan, have made a significant contribution to the field of oncology, shedding light on the molecular mechanisms underlying prostate cancer development and progression.

Statistics:

  • 95.5% of PC tumors overexpressed ECD, and their overexpression predicted shorter survival (NewsRx, September 16, 2025).
  • ECD mRNA and protein levels were significantly increased in PC patient tissues compared to normal tissues (Oncogene, 2025).
  • The RNA-seq analysis revealed a significant increase in mRNA levels of several glycolytic genes (Oncogene, 2025).
  • The study demonstrated that ECD overexpression led to a 2.5-fold increase in glucose uptake in PC cells (Oncogene, 2025).

Sources:

  • Oncogene, 2025. ECD, a novel androgen receptor target promotes prostate cancer tumorigenesis by regulating glycolysis.
  • NewsRx. Researchers at University of Nebraska Medical Center Report New Data on Prostate Cancer (ECD, a novel androgen receptor target promotes prostate cancer tumorigenesis by regulating glycolysis). Cancer Weekly. September 16, 2025; p 1944.